EMEA-003077-PIP01-21

Active substance

SARS-CoV-2 virus, beta-propiolactone inactivated adjuvanted with CpG 1018 (VLA2001)

Decision number

P/0184/2022

Pharmaceutical form(s)

Suspension for injection

Route(s) of administration

Intramuscular use

Decision type

P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)

Invented name	COVID-19 Vaccine (inactivated, adjuvanted) Valneva
Active substance	SARS-CoV-2 virus, beta-propiolactone inactivated adjuvanted with CpG 1018 (VLA2001)
Therapeutic area	Vaccines
Decision number	P/0184/2022
PIP number	EMEA-003077-PIP01-21
Pharmaceutical form(s)	Suspension for injection
Condition(s) / indication(s)	Prevention of Coronavirus disease 2019 (COVID-19)
Route(s) of administration	Intramuscular use
Contact for public enquiries	Valneva Austria GmbH E-mail: medinfo@valneva.com Tel. +43 20620-1124
Decision type	P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)